Moss Genomics Advances Blockchain Integration Strategy
Moss Genomics (OTCQB: MSSGF) has announced progress in its Ethereum Treasury Strategy, contributing 200 ETH with a commitment for an additional 800 ETH to the STRAT presale. STRAT is an on-chain smart contract platform for ETH-based capital flows.
The company is advancing its blockchain integration strategy, following a previously announced non-binding term sheet for investment in Genomes.io, a genomics platform focused on decentralized data storage and patient privacy. The STRAT presale aims to raise 6,900 ETH from strategic investors. Moss also noted ongoing progress toward completing its February 2025 private placement financing.
Moss Genomics (OTCQB: MSSGF) ha annunciato progressi nella sua strategia Ethereum Treasury, contribuendo con 200 ETH e impegnandosi a fornire ulteriori 800 ETH per la prevendita di STRAT. STRAT è una piattaforma di smart contract on-chain per i flussi di capitale basati su ETH.
L'azienda sta portando avanti la sua strategia di integrazione blockchain, dopo aver annunciato in precedenza un term sheet non vincolante per un investimento in Genomes.io, una piattaforma genomica focalizzata sull'archiviazione decentralizzata dei dati e sulla privacy dei pazienti. La prevendita di STRAT punta a raccogliere 6.900 ETH da investitori strategici. Moss ha inoltre segnalato progressi continui verso il completamento del finanziamento in collocamento privato previsto per febbraio 2025.
Moss Genomics (OTCQB: MSSGF) ha anunciado avances en su Estrategia de TesorerÃa de Ethereum, contribuyendo con 200 ETH y comprometiéndose a aportar 800 ETH adicionales para la preventa de STRAT. STRAT es una plataforma de contratos inteligentes on-chain para flujos de capital basados en ETH.
La compañÃa está avanzando en su estrategia de integración blockchain, tras haber anunciado previamente una hoja de términos no vinculante para una inversión en Genomes.io, una plataforma genómica centrada en el almacenamiento descentralizado de datos y la privacidad del paciente. La preventa de STRAT busca recaudar 6,900 ETH de inversores estratégicos. Moss también señaló progresos continuos hacia la finalización de su financiamiento mediante colocación privada prevista para febrero de 2025.
Moss Genomics (OTCQB: MSSGF)ê°€ ì´ë”리움 재무 ì „ëžµì—서 ì§„ì „ì� 발표하며 STRAT ì‚¬ì „ íŒë§¤ì—� 200 ETHë¥� ê¸°ì—¬í•˜ê³ ì¶”ê°€ë¡� 800 ETHë¥� 약ì†í–ˆìŠµë‹ˆë‹¤. STRATì€ ETH 기반 ìžë³¸ í름ì� 위한 온체ì� 스마íŠ� 계약 플랫í¼ìž…니다.
회사ëŠ� ì´ì „ì—� 발표í•� Genomes.io 투ìžì—� ê´€í•� 비구ì†ì ì¡°ê±´ 시트ë¥� 바탕으로 블ë¡ì²´ì¸ 통합 ì „ëžµì� ì¶”ì§„í•˜ê³ ìžˆìŠµë‹ˆë‹¤. Genomes.ioëŠ� ë¶„ì‚° ë°ì´í„� ì €ìž¥ê³¼ í™˜ìž í”„ë¼ì´ë²„ì‹œì— ì¤‘ì ì� ë‘� ìœ ì „ì²� 플랫í¼ìž…니다. STRAT ì‚¬ì „ íŒë§¤ëŠ� ì „ëžµì � 투ìžìžë¡œë¶€í„� 6,900 ETHë¥� 모금하는 ê²ƒì„ ëª©í‘œë¡� 합니ë‹�. MossëŠ� ë˜í•œ 2025ë…� 2ì›� ì˜ˆì •ë� 사모 íˆ¬ìž ìžê¸ˆ 조달 완료ë¥� 향한 ì§€ì†ì ì� ì§„ì „ì� 언급했습니다.
Moss Genomics (OTCQB : MSSGF) a annoncé des avancées dans sa stratégie de trésorerie Ethereum, en contribuant 200 ETH avec un engagement supplémentaire de 800 ETH pour la prévente de STRAT. STRAT est une plateforme de contrats intelligents on-chain pour les flux de capitaux basés sur ETH.
L'entreprise fait progresser sa stratégie d'intégration blockchain, suite à une lettre d'intention non contraignante précédemment annoncée pour un investissement dans Genomes.io, une plateforme génomique axée sur le stockage décentralisé des données et la confidentialité des patients. La prévente de STRAT vise à lever 6 900 ETH auprès d'investisseurs stratégiques. Moss a également signalé des progrès continus vers la finalisation de son financement en placement privé prévu pour février 2025.
Moss Genomics (OTCQB: MSSGF) hat Fortschritte bei seiner Ethereum Treasury-Strategie bekannt gegeben und 200 ETH beigetragen sowie eine zusätzliche Verpflichtung von 800 ETH für den STRAT-Vorverkauf eingegangen. STRAT ist eine On-Chain-Smart-Contract-Plattform für ETH-basierte Kapitalflüsse.
Das Unternehmen treibt seine Blockchain-Integrationsstrategie voran, nachdem zuvor ein unverbindliches Term Sheet für eine Investition in Genomes.io angekündigt wurde, eine Genomik-Plattform mit Fokus auf dezentrale Datenspeicherung und Patientendatenschutz. Der STRAT-Vorverkauf zielt darauf ab, 6.900 ETH von strategischen Investoren zu sammeln. Moss berichtete außerdem über kontinuierliche Fortschritte bei der Fertigstellung seiner Privatplatzierung im Februar 2025.
- Strategic investment of 1,000 ETH total commitment to blockchain infrastructure
- Partnership exploration with Genomes.io for decentralized genomic data management
- Participation in exclusive STRAT presale targeting 6,900 ETH raise
- Non-binding nature of Genomes.io term sheet indicates deal uncertainty
- Delayed completion of February 2025 private placement financing
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is providing an update on its Ethereum (ETH) Treasury Strategy. As part of this strategy, the Company has contributed 200 ETH with a commitment to contribute an additional 800 ETH to the presale of STRAT, an on-chain smart contract that enables ETH-based capital flows through algorithmic expansion and redemption mechanisms.
This contribution complements Moss's broader vision of incorporating blockchain infrastructure to support secure genomic data management. As previously disclosed on June 19, 2025, Moss entered into a non-binding term sheet for a strategic, non-controlling equity investment in Genomes.io, a genomics platform exploring decentralized data storage, patient-owned health records, and cryptographic privacy standards.
STRAT Presale Information
The STRAT presale is a private, on-chain capital raise targeting 6,900 ETH from a limited group of strategic investors. The contract's protocol is designed to operate without intermediaries or custodians, with all contributions and system mechanics handled transparently on the Ethereum blockchain.
Update on 2/3/25 Private Placement
The company wishes to advise that it is still taking steps towards completing the previously announced private placement financing from February 3, 2025, and further updates will be provided when warranted.
About Moss Genomics Inc.
Moss Genomics is developing a secure and user-controlled platform for genomic data, enabling individuals to vault their DNA, manage access permissions, and participate in research monetization opportunities. Moss is building on Ethereum-based infrastructure, with ETH used to fund development, DNA sequencing services, and future platform operations. The company's mission is to advance decentralized and privacy-preserving genomics through real-world applications in health, identity, and research.
CONTACT INFORMATION
Moss Genomics Inc.
Jack Liu, Chief Executive Officer and Director
Email: [email protected]
Telephone: 604-710-0124
Cautionary Statement:
The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This press release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this release, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as of the date of this release. Forward-looking statements are often, but not always, identified by words such as "expects," "plans," "anticipates," "intends," "believes," "estimates," "projects," "may," "could," "should," "will," "potential," "proposed," "scheduled," or similar expressions.
Such statements reflect the current views of management with respect to future events and are subject to a number of known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements.
In particular, this release contains forward-looking statements regarding the Company's Ethereum Treasury Strategy, its participation in the STRAT presale, and its general exploration of digital asset-related opportunities. These statements are not guarantees of future performance and do not constitute investment advice or a recommendation to engage in any activity involving digital assets. The Company's strategy involving digital assets is subject to change and may not result in any financial return or operational benefit.
Forward-looking statements are based on a number of assumptions believed by the Company to be reasonable at the time such statements are made, including assumptions related to the availability and stability of digital asset markets, regulatory conditions, cybersecurity infrastructure, internal governance, and general economic trends.
However, such assumptions involve significant known and unknown risks and uncertainties, including but not limited to: regulatory changes affecting blockchain or digital asset markets; adverse interpretations of applicable laws; the potential loss or theft of digital assets; technical or security failures; counterparty and custodial risks; limited liquidity or volatility of digital assets such as ETH; and broader market, operational, or political events beyond the Company's control.
Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, or intended. All forward-looking statements are qualified in their entirety by this cautionary statement.
Readers should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to revise or update forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are advised to consult with qualified professionals and consider their own risk tolerance and investment objectives before making any investment decisions.
To view the source version of this press release, please visit